Levi & Korsinsky reminds Pacira investors of class action lawsuit

Levi & Korsinsky is drawing attention to Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) investors about an ongoing class action lawsuit. Investors who acquired shares between May 5, 2017, and February 25, 2022, may join the lawsuit. The lawsuit involves claims that Pacira made false and misleading statements about the effectiveness of its EXPAREL product, leading to inflated stock prices. The lead plaintiff deadline for the lawsuit is March 14, 2025.

The lawsuit alleges that Pacira misled investors about its EXPAREL product’s effectiveness. EXPAREL is a long-lasting, non-opioid pain reliever used in surgical procedures. The allegations claim that Pacira falsely stated that EXPAREL was more effective than traditional bupivacaine-based local anesthetics. The lawsuit asserts that Pacira exaggerated the benefits of EXPAREL, leading investors to believe that the drug would generate immense profits for the company. As a result, Pacira’s stock price was artificially inflated during the class period.

Investors who purchased shares of Pacira between May 5, 2017, and February 25, 2022, may be eligible to participate in the class action lawsuit. The lead plaintiff deadline to join the lawsuit is March 14, 2025. Investors seeking to be a part of the lawsuit must file a motion by this deadline. The court will appoint one investor as the lead plaintiff to represent the class in the legal proceedings against Pacira.

Potential class members must actively participate in the lawsuit before the lead plaintiff deadline. By doing so, investors can ensure that their legal rights are protected and that they have a voice in the litigation process. The ultimate goal of the class action lawsuit is to hold Pacira accountable for its alleged false and misleading statements regarding the effectiveness of EXPAREL.

Investors who acquired shares of Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) between May 5, 2017, and February 25, 2022, are encouraged to contact Levi & Korsinsky. The law firm specializes in securities litigation and has a proven track record of success in handling complex class action lawsuits. Levi & Korsinsky aims to fight for investors’ rights and seek justice on their behalf. Investors have until March 14, 2025, to join the class action lawsuit as a potential lead plaintiff. Take action now to protect your rights and hold Pacira accountable for its alleged misconduct.